| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Articles |
1
Département de Biologie Clinique, Institut Gustave-Roussy, 94805 Villejuif, France.
2
Laboratoire de Biochimie, Centre Hospitalier de Meaux,
6/8 Rue Saint Fiacre, 77100 Meaux, France.
3
Laboratoire de Biochimie, Hôpital Boucicaut, 75015
Paris, France.
4
Laboratoire de Biochimie, Hôpital
Antoine-Béclère, 92141 Clamart, France.
5
Laboratoire de Radioimmunologie, Centre Paul-Papin,
49033 Angers, France.
6
Laboratoire de Biochimie, Centre Hospitalier
Pitié-Salpétrière, 75013 Paris, France.
7
Laboratoire de Biochimie, Hôpital Laennec, 75007
Paris, France.
8
Laboratoire de Biochimie, Hôpital Beaujon, 92110
Clichy, France.
a Author for correspondence. Fax 33-164353706; e-mail fthuillier{at}fc horus-medical.fr.
Only a few markers have been instrumental in the diagnosis of
cancer. In contrast, tumor markers play a critical role in the
monitoring of patients. The patient's clinical status and response to
treatment can be evaluated rapidly using the tumor marker half-life
(t1/2) and the tumor marker doubling time
(DT). This report reviews the interest of determining these kinetic
parameters for prostate-specific antigen, human chorionic gonadotropin,
-fetoprotein, carcinoembryonic antigen, cancer antigen (CA)
125, and CA 15-3. A rise in tumor markers (DT) is a yardstick with
which benign diseases can be distinguished from metastatic disease, and
the DT can be used to assess the efficacy of treatments. A decline in
the tumor marker concentration (t1/2) is a
predictor of possible residual disease if the timing of blood sampling
is soon after therapy. The discrepancies in results obtained by
different groups may be attributable to the multiplicity of
immunoassays, the intrinsic characteristics of each marker (e.g.,
antigen specificity, molecular heterogeneity, and associated forms),
individual factors (e.g., nonspecific increases and renal and hepatic
diseases) and methods used to calculate kinetics (e.g.,
exponential models and timing of blood sampling). This kinetic
approach could be of interest to optimize patient management.
The following articles in journals at HighWire Press have cited this article:
|
|
 |
|
  L Ranganath, W Taylor, L John, and Z Alfirevic Biochemical diagnosis of placental infarction/damage: acutely rising alkaline phosphatase Ann Clin Biochem, May 1, 2008; 45(3): 335 - 338. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Oudard, E. Banu, F. Scotte, A. Banu, J. Medioni, P. Beuzeboc, F. Joly, J.-M. Ferrero, F. Goldwasser, and J.-M. Andrieu Prostate-specific antigen doubling time before onset of chemotherapy as a predictor of survival for hormone-refractory prostate cancer patients Ann. Onc., November 1, 2007; 18(11): 1828 - 1833. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. G. Wahrenbrock and A. Varki Multiple Hepatic Receptors Cooperate to Eliminate Secretory Mucins Aberrantly Entering the Bloodstream: Are Circulating Cancer Mucins the "Tip of the Iceberg"? Cancer Res., February 15, 2006; 66(4): 2433 - 2441. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Barbet, L. Campion, F. Kraeber-Bodere, J.-F. Chatal, and and the GTE Study Group Prognostic Impact of Serum Calcitonin and Carcinoembryonic Antigen Doubling-Times in Patients with Medullary Thyroid Carcinoma J. Clin. Endocrinol. Metab., November 1, 2005; 90(11): 6077 - 6084. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. P. Lim Mining the Tumor Phosphoproteome for Cancer Markers Clin. Cancer Res., May 1, 2005; 11(9): 3163 - 3169. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. P. Graff, K. Chester, R. Begent, and K.D. Wittrup Directed evolution of an anti-carcinoembryonic antigen scFv with a 4-day monovalent dissociation half-time at 37{degrees}C Protein Eng. Des. Sel., April 1, 2004; 17(4): 293 - 304. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L.-Z. He, V. Ramakrishna, J. E. Connolly, X.-T. Wang, P. A. Smith, C. L. Jones, M. Valkova-Valchanova, A. Arunakumari, J. F. Treml, J. Goldstein, et al. A Novel Human Cancer Vaccine Elicits Cellular Responses to the Tumor-Associated Antigen, Human Chorionic Gonadotropin {beta} Clin. Cancer Res., March 15, 2004; 10(6): 1920 - 1927. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. T. Thomas, P. T. Bradshaw, B. H. Pollock, J. E. Montie, J. M.G. Taylor, H. D. Thames, P. W. McLaughlin, D. A. DeBiose, D. H. Hussey, and R. L. Wahl Indium-111-Capromab Pendetide Radioimmunoscintigraphy and Prognosis for Durable Biochemical Response to Salvage Radiation Therapy in Men After Failed Prostatectomy J. Clin. Oncol., May 1, 2003; 21(9): 1715 - 1721. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. R. Grzeda, T. Le Bui, C. N. Warner, T. L. Pirucki, L. M. Dewey, M. Babich, and J. A. Maggiore Measurement of Prostate-specific Antigen by Use of a Novel Blood Collection and Analytical System Clin. Chem., August 1, 2002; 48(8): 1272 - 1278. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. McDevitt, D. Ma, L. T. Lai, J. Simon, P. Borchardt, R. K. Frank, K. Wu, V. Pellegrini, M. J. Curcio, M. Miederer, et al. Tumor Therapy with Targeted Atomic Nanogenerators Science, November 16, 2001; 294(5546): 1537 - 1540. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Pautier, S. Ghione, S. Brailly-Tabard, C. Lhomme, P. Morice, and J.M. Bidart Are serum inhibin concentrations new markers of placental tumours in the course of chemotherapy? Hum. Reprod., November 1, 2001; 16(11): 2434 - 2437. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. McDevitt, E. Barendswaard, D. Ma, L. Lai, M. J. Curcio, G. Sgouros, A. M. Ballangrud, W.-H. Yang, R. D. Finn, V. Pellegrini, et al. An {{alpha}}-Particle Emitting Antibody ([213Bi]J591) for Radioimmunotherapy of Prostate Cancer Cancer Res., November 1, 2000; 60(21): 6095 - 6100. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
